NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading OSUR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making, and its recent performance has been weak, which adds to the uncertainty around its future prospects.
The market appears to have priced in a justified valuation, suggesting that OSUR is seen as cheap compared to its peers. However, there is an expectations gap, indicating that investors may anticipate further challenges ahead.
Management's priorities show mixed progress, particularly in revenue growth and commercialization in the diagnostics industry. The near-term risk of missing earnings is present, especially after the recent earnings miss.
The long-term thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. If these companies continue to perform well, it could positively impact OSUR, but any negative guidance from them could lead to further challenges.
In the next 1 to 3 years, OSUR's performance will depend heavily on both its internal execution and the broader healthcare sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Revenue at or below $27 million shows problems in the diagnostics market.
Confirms:Q2 2026 total revenues reported at $27 million or lower.
Disproves:Q2 2026 total revenues are above $30 million.
Why it matters: Revenue growth in the diagnostics industry is a key priority for OraSure. It shows how well the company is doing in a competitive market.
Confirms:Quarterly revenue growth in diagnostics exceeds 5% year over year.
Disproves:Quarterly revenue growth in diagnostics falls below 0% year over year.
Why it matters: This report will show if revenue growth in diagnostics is improving. Investors will focus on any signs of recovery.
Confirms one read:Q2 revenue growth exceeds 5% year over year, indicating a positive trend.
Confirms the other:Q2 revenue growth is below 0%. This shows ongoing problems in the diagnostics market.
Why it matters: Achieving a gross margin in the low 40% range is key for financial stability.
Confirms:Gross margin reported at 41% or higher in Q2 2026.
Disproves:Gross margin reported below 40% in Q2 2026.
